Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial

Background. Modified vaccinia Ankara (MVA-BN, IMVAMUNE) is emerging as a primary immunogen and as a delivery system to treat or prevent a wide range of diseases. Defining the safety and immunogenicity of MVA-BN in key populations is therefore important. Methods. We performed a dose-escalation study...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Walsh, Stephen R., Wilck, Marissa B., Dominguez, David J., Zablowsky, Elise, Bajimaya, Shringkhala, Gagne, Lisa S., Verrill, Kelly A., Kleinjan, Jane A., Patel, Alka, Zhang, Ying, Hill, Heather, Acharyya, Aruna, Fisher, David C., Antin, Joseph H., Seaman, Michael S., Dolin, Raphael, Baden, Lindsey R.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2013
Materias:
Major Articles and Brief Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3654753/
https://ncbi.nlm.nih.gov/pubmed/23482644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jit105
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares